Advertisement
UK markets close in 6 hours 28 minutes
  • FTSE 100

    8,109.16
    +30.30 (+0.38%)
     
  • FTSE 250

    19,812.40
    +210.42 (+1.07%)
     
  • AIM

    755.94
    +2.82 (+0.37%)
     
  • GBP/EUR

    1.1659
    +0.0003 (+0.02%)
     
  • GBP/USD

    1.2524
    +0.0013 (+0.10%)
     
  • Bitcoin GBP

    51,432.94
    +410.47 (+0.80%)
     
  • CMC Crypto 200

    1,390.31
    -6.22 (-0.45%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.76
    +0.19 (+0.23%)
     
  • GOLD FUTURES

    2,360.00
    +17.50 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,059.05
    +141.77 (+0.79%)
     
  • CAC 40

    8,043.72
    +27.07 (+0.34%)
     

What Could Drive Amgen’s Long-Term Growth?

What Could Drive Amgen’s Long-Term Growth?

In January 2018, the European Commission (or EC) approved Amgen’s (AMGN) and Allergan’s (AGN) Marketing Authorization Application (or MAA) for Mvasi, a biosimilar to Roche’s (RHHBY) Avastin (bevacizumab). Amgen’s Mvasi became the first bevacizumab biosimilar to be approved by the EC for the treatment of particular types of cancer. In January 2018, Amgen presented positive results from its Phase 3b LIBERTY trial.